Momo

Momo is a biotechnology company focused on expanding the druggable proteome through a proprietary chemoproteomics platform. Founded by leading researchers from UC Berkeley, the company utilizes advanced chemical biology techniques to identify and target novel binding pockets on proteins previously considered "undruggable." Their primary focus is on developing covalent small molecule therapeutics for oncology indications where traditional approaches have failed. The company's platform enables the systematic discovery of reactive sites across the proteome, facilitating the design of highly selective and potent drug candidates.